Your browser is no longer supported. Please, upgrade your browser.
ZOM Zomedica Pharmaceuticals Corp. daily Stock Chart
Zomedica Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-0.18 Insider Own35.80% Shs Outstand115.42M Perf Week6.08%
Market Cap30.01M Forward P/E- EPS next Y- Insider Trans- Shs Float45.79M Perf Month-3.70%
Income-16.60M PEG- EPS next Q- Inst Own3.50% Short Float2.20% Perf Quarter-63.89%
Sales- P/S- EPS this Y-93.10% Inst Trans1.61% Short Ratio2.88 Perf Half Y-81.56%
Book/sh-0.02 P/B- EPS next Y- ROA- Target Price- Perf Year-86.73%
Cash/sh0.02 P/C13.05 EPS next 5Y- ROE- 52W Range0.20 - 2.98 Perf YTD-78.86%
Dividend- P/FCF- EPS past 5Y7.00% ROI- 52W High-91.28% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low30.26% ATR0.04
Employees27 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)43.15 Volatility23.70% 17.48%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.55 Prev Close0.26
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume350.27K Price0.26
Recom- SMA20-8.54% SMA50-16.51% SMA200-75.68% Volume193,510 Change0.00%
Jun-13-19 06:55AM  Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform GlobeNewswire +10.20%
Jun-12-19 04:35PM  Zomedica to Present at Raymond James Life Sciences and MedTech Conference GlobeNewswire -13.05%
Jun-10-19 06:00AM  Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares GlobeNewswire +6.57%
May-21-19 06:55AM  Zomedica Announces Achievement of Product Development Milestones on its TRUFORMA Point-of-Care Diagnostic Platform GlobeNewswire +12.96%
May-10-19 05:21PM  Zomedica Announces First Quarter 2019 Financial Results GlobeNewswire +6.69%
06:00AM  Zomedica Announces Private Placement of Preferred Shares GlobeNewswire
Mar-26-19 06:00AM  Zomedica Pharmaceuticals Corp. Announces Pricing of $3 Million Underwritten Public Offering of Common Shares GlobeNewswire -43.82%
Mar-25-19 04:01PM  Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering of Common Shares GlobeNewswire -12.38%
Mar-05-19 06:55AM  Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate Updates GlobeNewswire +6.77%
Feb-26-19 04:05PM  Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results GlobeNewswire
Jan-15-19 06:55AM  Zomedica Appoints Dr. Bonnie Bragdon as Vice President of Veterinary Affairs GlobeNewswire +5.36%
Jan-14-19 06:55AM  Zomedica Announces $4.28 Million Private Placement Closing and Corporate Update GlobeNewswire -7.44%
Dec-20-18 05:23PM  Zomedica Provides Update on Pipeline Development and Announces At-The-Market Offering Program GlobeNewswire +9.32%
Dec-19-18 06:00AM  IncellDx and Zomedica Sign Diagnostic CTC Assay Development Agreement for Canine Cancer PR Newswire -13.87%
Nov-28-18 09:53AM  Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors Zacks +12.34%
Nov-27-18 06:51AM  Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform GlobeNewswire -10.47%
06:50AM  Zomedica Announces $10 Million Private Offering of Common Shares GlobeNewswire
Nov-26-18 07:25AM  Analysis: Positioning to Benefit within Dominion Energy Midstream Partners, LP, Blue Capital Reinsurance, CRH Medical, Friedman Industries, CM Finance, and Zomedica Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +11.69%
Nov-13-18 04:47PM  Zomedica Pharmaceuticals Corp. Announces Third Quarter 2018 Financial Results GlobeNewswire -5.17%
Nov-12-18 04:30PM  Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI GlobeNewswire
Oct-16-18 09:00AM  SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. ACCESSWIRE
Sep-18-18 06:55AM  Zomedica Pharmaceuticals Corp. to Present at LD Micro NYC Summit and Cantor 2018 Global Healthcare Conference GlobeNewswire
Aug-15-18 04:15PM  Zomedica Announces 2018 Annual Meeting Results GlobeNewswire
Aug-09-18 04:01PM  Zomedica Pharmaceuticals Corp. Announces Second Quarter 2018 Financial Results GlobeNewswire
Jun-28-18 08:57PM  Zomedica Announces Interim Closing and Extension of Its Private Offering of Common Shares GlobeNewswire
Jun-25-18 05:59PM  Zomedica Joins Russell 3000 and Russell Microcap® Indexes GlobeNewswire -15.77%
Jun-19-18 06:54AM  Zomedica Provides Product Development Update GlobeNewswire
Jun-14-18 06:15PM  Zomedica Announces Changes to Commercialization Leadership Team GlobeNewswire
May-15-18 04:06PM  Zomedica Pharmaceuticals Corp. Announces First Quarter 2018 Financial Results GlobeNewswire
04:01PM  Zomedica Announces Up to $10 Million Private Offering of Common Shares GlobeNewswire
May-14-18 07:30AM  Wired News Zomedica Inks Deal with Seraph to Develop and Market Seraphs Novel Pathogen Detection System for Veterinarians ACCESSWIRE -5.00%
May-10-18 06:55AM  Zomedica Signs Agreement With Seraph Biosciences for Innovative Veterinary Point-of-Care Diagnostic GlobeNewswire
May-07-18 06:55AM  Zomedica to Present at 2018 Disruptive Growth & Healthcare Conference GlobeNewswire
Mar-26-18 09:00AM  SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) ACCESSWIRE
Mar-07-18 06:55AM  Zomedica to Present at 30th Annual ROTH Conference GlobeNewswire
Feb-28-18 04:11PM  Zomedica Pharmaceuticals Corp. Announces Year End 2017 Financial Results GlobeNewswire
Feb-20-18 06:55AM  Zomedica to Participate in the Bank of America Merrill Lynch Animal Health Summit GlobeNewswire
Dec-01-17 09:00AM  SeeThruEquity Initiates Coverage on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) with a Price Target of $3.24 ACCESSWIRE -6.90%
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.